CLRB Stock Analysis: Buy, Sell, or Hold?
CLRB - Cellectar Biosciences INC NEW
$2.50
-0.09 (-3.47%)
âŧ
5d:
-2.34%
30d:
+3.73%
90d:
-21.88%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CLRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLRB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLRB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLRB is currently trading at $2.50, which is considered slightly low relative to its 30-day fair value range of $2.48 to $2.61.
Technical Outlook: Technically, CLRB is in a downtrend. The price is currently testing key support at $2.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: CLRB scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+344.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLRB is in a downtrend. The price is currently testing key support at $2.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: CLRB scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+344.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.48 -
$2.61
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 344.0% below Wall St target ($11.50)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.48 -
$2.61
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.45
Resistance Level
$2.70
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.35
Wall Street Target
$11.50
(+344.0%)
Share & Embed Analysis
Last updated: August 24, 2026 3:01 PM ET
Data refreshes hourly during market hours. Next update: 4:01 PM
Data refreshes hourly during market hours. Next update: 4:01 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 39 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 40 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 62 BUY |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 48 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
